Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level

Yutong Li; Bin Pan; Guo Chen; Ying Wu

doi:doi:10.11648/j.ajcem.20210901.14

| Peer-Reviewed

Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level

Yutong Li, Bin Pan, Guo Chen, Ying Wu

Published in American Journal of Clinical and Experimental Medicine (Volume 9, Issue 1)

Received: 2 February 2021 Accepted: 12 February 2021 Published: 30 March 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective: Phloroglucinol is a myotropic, non-atropine and non-papaverine smooth muscle antispasmodic which directly acts on the smooth muscles of the gastrointestinal tract and the urogenital tract with no anticholinergic effect, no symptoms like xerostomia, visual impairment, dysuria, hypotension, increased heart rate, and arrhythmia etc. To investigate the efficacy of phloroglucinol tamsulosin combination therapy for medical expulsion of lower ureteral calculi and influence on patients’ Cys-C level. Methods: Equally randomized 136 patients with lower ureteral calculi in our hospital into mono therapy group (phloroglucinol alone) and combination therapy group (additional tamsulosin was advised). The expulsion rate, expulsion time, stone diameter and levels of IL-10, CRP, NGAL, Cys-C, KIM-1 were compared between two groups, also with the effectiveness and the rate of adverse reactions. Results: The combination therapy group showed higher expulsion rate (P<0.05) and shorter expulsion time (P<0.05) than that of the mono therapy group and the stone diameter was slightly larger as well (P<0.05). Also, patients under combination treatment had elevated IL-10, CRP, NGAL, Cys-C and KIM-1 levels and a better overall response rate (P<0.05) while it was associated with a slightly higher rate of adverse reactions (P>0.05). Conclusions: Phloroglucinol tamsulosin combination therapy had clear advantages on medical expulsion of lower ureteral calculi in respect of higher expulsion rate and elevated IL-10, CRP, NGAL, Cys-C and KIM-1 levels with larger stone diameter in a shorter time.

Published in	American Journal of Clinical and Experimental Medicine (Volume 9, Issue 1)
DOI	10.11648/j.ajcem.20210901.14
Page(s)	17-21
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Phloroglucinol Injection, Tamsulosin, Lower Ureteral Calculi

References

[1]	Corbo J, Wang J. Kidney et al. Emerg Med Clin North Am. 2019 Nov; 37 (4): 637-648.
[2]	Fontenelle LF, Sarti TD. Kidney Stones: Treatment and Prevention. Am Fam Physician. 2019 Apr 15; 99 (8): 490-496.
[3]	Yamashita S, Kohjimoto Y, Iguchi T, et al. Ureteralwall volume at ureteral stone site is a critical predictor for shock wavelithotripsy outcomes: comparison with ureteral wall thickness and area. Urolithiasis. 2019 Aug 23.
[4]	Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi [J]. J Urol, 2005, 174 (1): 167-172.
[5]	Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009; 23: 1913.
[6]	Yakoubi R, Lemdani M, Monga M, et al. Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 2011; 186: 928.
[7]	Norris RD, Sur RL, Springhart WP, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008; 71: 792.
[8]	Beiko DT, Watterson JD, Knudsen BE, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol 2004; 18: 723.
[9]	Skolarikos A. Medical treatment of urinary stones. Curr Opin Urol. 2018 Sep; 28 (5): 403-407.
[10]	Probst C E, Denstedt J D, Razvi H. Preoperative indications for percutaneous nephrolithotr-ipsy in 2009 [J]. J Endourol, 2009, 23 (10): 1557-1561.
[11]	Ouyang W, O'Garra A. IL-10 Family Cytokines IL-10 and IL-22: from BasicScience to Clinical Translation. Immunity. 2019 Apr 16; 50 (4): 871-891.
[12]	Xue M, Qiqige C, Zhang Q, et al. Effects of TumorNecrosis Factor α (TNF-α) and Interleukina 10 (IL-10) on Intercellular CellAdhesion Molecule-1 (ICAM-1) and Cluster of Differentiation 31 (CD31) in Human Coronary Artery Endothelial Cells. Med Sci Monit. 2018 Jun 27; 24: 4433-4439.
[13]	Sun MZ, Chen HM, Zhou ZW, et al. Neutrophil gelatinase-associated apolipoprotein in patients with iodine-contrast nephropathy. J Biol Regul Homeost Agents. 2019 Jul-Aug; 33 (4): 1171-1176.
[14]	Otsuka T, Tanaka A, Suemaru K, et al. Evaluation of the clinical application of eystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin [J]. J Clin PharmThor, 2008, 33 (3): 227.235.
[15]	Bakoush O, Grubb A, Rippe B, et al. Inaccuracy of GFR predictions by plasma cystatin C in patients without kidney dysfunction and in advanced kidney disease [J]. Clin Nephrol, 2008, 69 (5): 331-338.
[16]	Vaidya V S, Ozer J S, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies [J]. Nat Biotechnol, 2010, 28 (5): 478-485.
[17]	Zuo J, Khan A, Glenton P A, et al. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxyL-proline-induced hyperoxaluria in the male Sprague Dawley rats [J]. Nephrol Dial Transplant, 2011, 26 (6): 1785-1796.
[18]	Malyszko J, Koc-Zorawska E, Malyszko J S, et al. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients [J]. Transplant Proc, 2010, 42 (10): 3957-3959.

Cite This Article

Plain Text BibTeX RIS

APA Style

Yutong Li, Bin Pan, Guo Chen, Ying Wu. (2021). Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level. American Journal of Clinical and Experimental Medicine, 9(1), 17-21. https://doi.org/10.11648/j.ajcem.20210901.14

Copy | Download

ACS Style

Yutong Li; Bin Pan; Guo Chen; Ying Wu. Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level. Am. J. Clin. Exp. Med. 2021, 9(1), 17-21. doi: 10.11648/j.ajcem.20210901.14

Copy | Download

AMA Style

Yutong Li, Bin Pan, Guo Chen, Ying Wu. Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level. Am J Clin Exp Med. 2021;9(1):17-21. doi: 10.11648/j.ajcem.20210901.14

Copy | Download

@article{10.11648/j.ajcem.20210901.14,
  author = {Yutong Li and Bin Pan and Guo Chen and Ying Wu},
  title = {Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {9},
  number = {1},
  pages = {17-21},
  doi = {10.11648/j.ajcem.20210901.14},
  url = {https://doi.org/10.11648/j.ajcem.20210901.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210901.14},
  abstract = {Objective: Phloroglucinol is a myotropic, non-atropine and non-papaverine smooth muscle antispasmodic which directly acts on the smooth muscles of the gastrointestinal tract and the urogenital tract with no anticholinergic effect, no symptoms like xerostomia, visual impairment, dysuria, hypotension, increased heart rate, and arrhythmia etc. To investigate the efficacy of phloroglucinol tamsulosin combination therapy for medical expulsion of lower ureteral calculi and influence on patients’ Cys-C level. Methods: Equally randomized 136 patients with lower ureteral calculi in our hospital into mono therapy group (phloroglucinol alone) and combination therapy group (additional tamsulosin was advised). The expulsion rate, expulsion time, stone diameter and levels of IL-10, CRP, NGAL, Cys-C, KIM-1 were compared between two groups, also with the effectiveness and the rate of adverse reactions. Results: The combination therapy group showed higher expulsion rate (P0.05). Conclusions: Phloroglucinol tamsulosin combination therapy had clear advantages on medical expulsion of lower ureteral calculi in respect of higher expulsion rate and elevated IL-10, CRP, NGAL, Cys-C and KIM-1 levels with larger stone diameter in a shorter time.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level
AU  - Yutong Li
AU  - Bin Pan
AU  - Guo Chen
AU  - Ying Wu
Y1  - 2021/03/30
PY  - 2021
N1  - https://doi.org/10.11648/j.ajcem.20210901.14
DO  - 10.11648/j.ajcem.20210901.14
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 17
EP  - 21
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20210901.14
AB  - Objective: Phloroglucinol is a myotropic, non-atropine and non-papaverine smooth muscle antispasmodic which directly acts on the smooth muscles of the gastrointestinal tract and the urogenital tract with no anticholinergic effect, no symptoms like xerostomia, visual impairment, dysuria, hypotension, increased heart rate, and arrhythmia etc. To investigate the efficacy of phloroglucinol tamsulosin combination therapy for medical expulsion of lower ureteral calculi and influence on patients’ Cys-C level. Methods: Equally randomized 136 patients with lower ureteral calculi in our hospital into mono therapy group (phloroglucinol alone) and combination therapy group (additional tamsulosin was advised). The expulsion rate, expulsion time, stone diameter and levels of IL-10, CRP, NGAL, Cys-C, KIM-1 were compared between two groups, also with the effectiveness and the rate of adverse reactions. Results: The combination therapy group showed higher expulsion rate (P0.05). Conclusions: Phloroglucinol tamsulosin combination therapy had clear advantages on medical expulsion of lower ureteral calculi in respect of higher expulsion rate and elevated IL-10, CRP, NGAL, Cys-C and KIM-1 levels with larger stone diameter in a shorter time.
VL  - 9
IS  - 1
ER  -

Copy | Download

Author Information

Yutong Li

The First Affiliated Hospital of Jinan University, Guangzhou, China
Bin Pan

The First Affiliated Hospital of Jinan University, Guangzhou, China
Guo Chen

The First Affiliated Hospital of Jinan University, Guangzhou, China
Ying Wu

The First Affiliated Hospital of Jinan University, Guangzhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Yutong Li, Bin Pan, Guo Chen, Ying Wu. (2021). Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level. American Journal of Clinical and Experimental Medicine, 9(1), 17-21. https://doi.org/10.11648/j.ajcem.20210901.14

Copy | Download

ACS Style

Yutong Li; Bin Pan; Guo Chen; Ying Wu. Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level. Am. J. Clin. Exp. Med. 2021, 9(1), 17-21. doi: 10.11648/j.ajcem.20210901.14

Copy | Download

AMA Style

Yutong Li, Bin Pan, Guo Chen, Ying Wu. Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level. Am J Clin Exp Med. 2021;9(1):17-21. doi: 10.11648/j.ajcem.20210901.14

Copy | Download

@article{10.11648/j.ajcem.20210901.14,
  author = {Yutong Li and Bin Pan and Guo Chen and Ying Wu},
  title = {Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {9},
  number = {1},
  pages = {17-21},
  doi = {10.11648/j.ajcem.20210901.14},
  url = {https://doi.org/10.11648/j.ajcem.20210901.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210901.14},
  abstract = {Objective: Phloroglucinol is a myotropic, non-atropine and non-papaverine smooth muscle antispasmodic which directly acts on the smooth muscles of the gastrointestinal tract and the urogenital tract with no anticholinergic effect, no symptoms like xerostomia, visual impairment, dysuria, hypotension, increased heart rate, and arrhythmia etc. To investigate the efficacy of phloroglucinol tamsulosin combination therapy for medical expulsion of lower ureteral calculi and influence on patients’ Cys-C level. Methods: Equally randomized 136 patients with lower ureteral calculi in our hospital into mono therapy group (phloroglucinol alone) and combination therapy group (additional tamsulosin was advised). The expulsion rate, expulsion time, stone diameter and levels of IL-10, CRP, NGAL, Cys-C, KIM-1 were compared between two groups, also with the effectiveness and the rate of adverse reactions. Results: The combination therapy group showed higher expulsion rate (P0.05). Conclusions: Phloroglucinol tamsulosin combination therapy had clear advantages on medical expulsion of lower ureteral calculi in respect of higher expulsion rate and elevated IL-10, CRP, NGAL, Cys-C and KIM-1 levels with larger stone diameter in a shorter time.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Efficacy of Phloroglucinol Tamsulosin Combination Therapy for Medical Expulsion of Lower Ureteral Calculi and Influence on Patients’ Cys-C Level
AU  - Yutong Li
AU  - Bin Pan
AU  - Guo Chen
AU  - Ying Wu
Y1  - 2021/03/30
PY  - 2021
N1  - https://doi.org/10.11648/j.ajcem.20210901.14
DO  - 10.11648/j.ajcem.20210901.14
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 17
EP  - 21
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20210901.14
AB  - Objective: Phloroglucinol is a myotropic, non-atropine and non-papaverine smooth muscle antispasmodic which directly acts on the smooth muscles of the gastrointestinal tract and the urogenital tract with no anticholinergic effect, no symptoms like xerostomia, visual impairment, dysuria, hypotension, increased heart rate, and arrhythmia etc. To investigate the efficacy of phloroglucinol tamsulosin combination therapy for medical expulsion of lower ureteral calculi and influence on patients’ Cys-C level. Methods: Equally randomized 136 patients with lower ureteral calculi in our hospital into mono therapy group (phloroglucinol alone) and combination therapy group (additional tamsulosin was advised). The expulsion rate, expulsion time, stone diameter and levels of IL-10, CRP, NGAL, Cys-C, KIM-1 were compared between two groups, also with the effectiveness and the rate of adverse reactions. Results: The combination therapy group showed higher expulsion rate (P0.05). Conclusions: Phloroglucinol tamsulosin combination therapy had clear advantages on medical expulsion of lower ureteral calculi in respect of higher expulsion rate and elevated IL-10, CRP, NGAL, Cys-C and KIM-1 levels with larger stone diameter in a shorter time.
VL  - 9
IS  - 1
ER  -

Copy | Download